Everett Rand Sutherland - 14 Sep 2021 Form 4 Insider Report for Translate Bio, Inc.

Reporting relationship: President
Issuer ticker: N/A
Reported as of: 14 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Sep 2021, 19:34:57 UTC
Next SEC filing: 26 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Paul D. Burgess, as attorney-in-fact for E. Rand Sutherland

Key filing fact

Everett Rand Sutherland filed Form 4 for Translate Bio, Inc. on 14 Sep 2021.

Key facts

This page summarizes Everett Rand Sutherland's Form 4 filing for Translate Bio, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Sep 2021, 19:34.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -300,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $16.37
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

Footnote F2

This option was granted on March 22, 2021. This option will vest as to 25% of the shares on March 22, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 22, 2025.